骨转换标志物在监测绝经后骨质疏松症停用口服双膦酸盐治疗中的临床效用
该研究纳入完成2年口服双膦酸盐治疗且骨密度T值大于-2.5、临床认为可停药绝经后骨质疏松女性,进行2年观察性研究,用CTX和PINP评估停药后生化反应,发现骨转换标志物升幅超过最小显著变化和/或参考均值者总髋骨密度下降更多,提示骨转换标志物可能有助于监测停药患者。
要点
- 停药48周时,66%女性CTX升幅超过最小显著变化,72%女性PINP升幅超过最小显著变化。
- 停药48周时,64%女性CTX高于参考均值,42%女性PINP高于参考均值。
- 骨转换标志物升幅最大者总髋骨密度下降大于持续抑制者,CTX平均差异-2.98%(95%CI -4.75至-1.22,P<0.001),PINP平均差异-2.25%(95%CI -4.46至-0.032,P=0.046)。
核心结论
- 停用双膦酸盐后测量骨转换标志物可能有助于评估暂停治疗的患者。
- 骨转换标志物升幅超过最小显著变化和/或参考均值反映治疗效应丧失,并识别可能出现骨密度下降的患者。
- 此类变化可为重新开始治疗提供指征。
研究设计与样本
- 研究纳入完成一项三种口服双膦酸盐随机研究的绝经后骨质疏松女性,治疗后骨密度T值大于-2.5且临床认为适合停药者受邀参加进一步2年观察性研究。
- 共50名女性完成研究,通过CTX和PINP评估生化反应,停药定义采用两项标准:升幅大于最小显著变化和升幅高于参考均值。
主要发现
- 停药48周时,66%女性CTX升幅大于最小显著变化,72%女性PINP升幅大于最小显著变化。
- 停药48周时,64%女性CTX高于参考均值,42%女性PINP高于参考均值。
- 骨转换标志物升幅最大者总髋骨密度下降大于持续抑制者,CTX平均差异-2.98%(95%CI -4.75至-1.22,P<0.001),PINP平均差异-2.25%(95%CI -4.46至-0.032,P=0.046)。
关键数值与推荐
- 停药生化反应标准1:骨转换标志物升幅大于最小显著变化。
- 停药生化反应标准2:骨转换标志物升幅高于参考均值。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: Bone markers may be useful to monitor response to treatment withdrawal in osteoporosis. We used two criteria for investigating the change in BTMs after withdrawal of bisphosphonate treatment. A larger increase in BTMs was associated with greater bone loss. Bone markers may be useful in monitoring of patients taking a pause from treatment. INTRODUCTION: Measurement of bone turnover markers (BTMs) may be useful to monitor offset of treatment with bisphosphonates (BP) in osteoporosis. We assessed the effect of withdrawal of BP treatment by comparing the changes in BTMs and total hip (TH) bone density (BMD). METHODS: We studied postmenopausal osteoporotic women who had completed a randomised study of three oral BPs. After 2 years of treatment, participants with BMD T-score > - 2.5 and in whom it was considered clinically appropriate to discontinue treatment, were invited to participate in a further 2-year observational study. Biochemical response was assessed using BTMs (CTX and PINP) with offset being defined by two criteria: (1) an increase greater than the least significant change (LSC) and (2) an increase above the reference mean value. RESULTS: Fifty women completed the study. At 48 weeks after stopping BPs, CTX was greater than the LSC for 66% of women and PINP 72%; CTX was above the reference mean for 64% of women and PINP 42%. The decrease in THBMD was greater for women with the largest increase in BTM compared to those with continued suppression (mean difference for CTX was - 2.98%, 95%CI - 4.75 to - 1.22, P < 0.001, PINP - 2.25%, 95% CI - 4.46 to - 0.032, P = 0.046). CONCLUSION: The measurement of BTM after withdrawal of BPs is potentially useful to evaluate patients that are taking a pause from treatment. An increase in BTMs more than the LSC and/or reference mean reflects loss of treatment effect and identifies patients that are likely to have a decrease in BMD. Such changes could provide an indication for reintroduction of treatment.
引用
- Naylor KE, McCloskey EV, Jacques RM, et al. Clinical utility of bone turnover markers in monitoring the withdrawal of treatment with oral bisphosphonates in postmenopausal osteoporosis. Osteoporos Int. 2019. PMID: 30613868. doi:10.1007/s00198-018-04823-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。